ロード中...
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
For decades, cytotoxic therapy was considered ineffective for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Earlier therapies such as estramustine and mitoxantrone received regulatory approval based upon improvement in palliative endpoints. In 2004, docetaxel became the f...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003844/ https://ncbi.nlm.nih.gov/pubmed/24883107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287214528557 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|